Compare · LYRA vs MDLN
LYRA vs MDLN
Side-by-side comparison of Lyra Therapeutics Inc. (LYRA) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LYRA and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $47.31B, about 1039.3x LYRA ($45.5M).
- Over the past year, LYRA is down 96.8% and MDLN is down 11.6% - MDLN leads by 85.1 points.
- MDLN has hit the wire 21 times in the past 4 weeks while LYRA has been quiet.
- MDLN has more recent analyst coverage (25 ratings vs 7 for LYRA).
- Company
- Lyra Therapeutics Inc.
- Medline Inc.
- Price
- $0.49-61.33%
- $36.01+6.54%
- Market cap
- $45.5M
- $47.31B
- 1M return
- +0.00%
- -8.80%
- 1Y return
- -96.79%
- -11.64%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2025
- News (4w)
- 0
- 21
- Recent ratings
- 7
- 25
Lyra Therapeutics Inc.
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Latest LYRA
- Director Smith W Bradford returned 640 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 15-12G filed by Lyra Therapeutics Inc.
- SEC Form 25 filed by Lyra Therapeutics Inc.
- SEC Form 8-K filed by Lyra Therapeutics Inc.
- Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC
- SEC Form 8-K filed by Lyra Therapeutics Inc.
- SEC Form 4 filed by Palasis Maria
- SEC Form 4 filed by Cavalier Jason
- SEC Form 10-K filed by Lyra Therapeutics Inc.
- SEC Form EFFECT filed by Lyra Therapeutics Inc.
Latest MDLN
- Principal Accounting Officer Corcoran Jessi L bought $170,750 worth of shares (5,000 units at $34.15) (SEC Form 4)
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update